A minimally invasive assay detects BRCA1 and BRCA2 protein truncations indicative of the presence of a germline mutation

2000 2000

Other formats: Order a copy

Abstract (summary)

Family members with a heritable mutation in the BRCA1 or BRCA2 gene have up to an 85% life-long risk of contracting one or more of the cancers associated with a genetic alteration to these genes. The inheritance risks of a BRCA alteration to first and second-degree relatives of affected individuals are 50% and 25%, respectively. Currently, members from high-risk families can be tested for the presence of BRCA1 or BRCA2 mutations by gene sequencing of blood cell DNA. This test is expensive and generally is not reimbursed by insurance carriers.

Over 85% of BRCA1 and BRCA2 mutations are reported to result in the production of a truncated protein, from which the carboxy terminal end sequences of their respective protein is missing.

In preliminary studies, using antibodies specific for the amino acid terminal or the carboxy terminal of the BRCA1 protein, we demonstrated that immunohistochemical analysis of surgical specimens, consisting of matched ovarian tumor and normal uninvolved tissue, identified BRCA1 protein truncations in two matched samples. Each BRCA1 protein truncation was shown to be indicative of the presence of a BRCA1 germline mutation.

Human buccal cells were then investigated as a minimally invasive cell source for this assay. Buccal cells were shown to express BRCA1 and BRCA2 protein immunohistochemically using distinct antibodies for the BRCA1 and BRCA2 protein terminals. Transcription of the BRCA1 and BRCA2 gene within buccal cells was also shown to occur by RT-PCR.

A double blind study was then conducted using blood DNA and buccal cells collected from thirteen high-risk patients for carrying a germline BRCA1 or BRCA2 mutation. Mutation analysis (PCR, SSCP, and gene sequencing) was performed on DNA. Immunohistochemical analysis for the BRCA1 and BRCA2 protein was performed on cytospun deposited buccal cells. The buccal cell assay correctly predicted the presence of six germline BRCA1 mutations, three germline BRCA2 mutations, and three with no mutations. One predicted germline BRCA2 mutation did not correlate with DNA sequencing results. Based on these results, this assay exhibited a 100% negative predictive value and 90% positive predictive value.

Indexing (details)

Molecular biology;
0307: Molecular biology
0992: Oncology
Identifier / keyword
Health and environmental sciences; Biological sciences; BRCA; Breast cancer; Cancer detection; Germline mutation; Ovarian cancer; Protein truncations
A minimally invasive assay detects BRCA1 and BRCA2 protein truncations indicative of the presence of a germline mutation
Byrne, Timothy John
Number of pages
Publication year
Degree date
School code
DAI-B 61/09, Dissertation Abstracts International
Place of publication
Ann Arbor
Country of publication
United States
9780599956421, 0599956429
Autio, Wesley R.
University of Massachusetts Amherst
University location
United States -- Massachusetts
Source type
Dissertations & Theses
Document type
Dissertation/thesis number
ProQuest document ID
Database copyright ProQuest LLC; ProQuest does not claim copyright in the individual underlying works.
Document URL
Access the complete full text

You can get the full text of this document if it is part of your institution's ProQuest subscription.

Try one of the following:

  • Connect to ProQuest through your library network and search for the document from there.
  • Request the document from your library.
  • Go to the ProQuest login page and enter a ProQuest or My Research username / password.